Morgan Stanley Upgrades Axsome Therapeutics to Overweight, Raises Price Target to $115
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit upgraded Axsome Therapeutics (NASDAQ:AXSM) from Equal-Weight to Overweight and increased the price target from $90 to $115.

April 29, 2024 | 9:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley upgraded Axsome Therapeutics to Overweight and raised its price target to $115.
Analyst upgrades typically lead to positive short-term price movements. The substantial increase in the price target from $90 to $115 by a reputable firm like Morgan Stanley suggests a strong confidence in Axsome Therapeutics' future performance, likely leading to increased investor interest and a potential rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100